{
    "title": "COVID-19 Drug Development.",
    "doc_id": "34866128",
    "writer": "Kim S.",
    "year": "2022",
    "summary": "Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID- â€¦",
    "abstract": "Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/34866128/",
    "clean_text": "covid drug development vaccines such as mrna vaccines and virus vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus sars cov as the causative agent of covid diagnostics vaccines and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease covid diagnostic tools based on rt pcr were developed early in the covid pandemic and were urgently required for quarantine testing tracing and isolation vaccines such as mrna vaccines and virus vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus sars cov as the causative agent of covid drug development has been conducted in various ways including drug repurposing convalescent plasma therapy and monoclonal antibody development among the above efforts this review examines covid drug development along with the related and upcoming challenges"
}